Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19 Tumors.
作者信息
Grover Natalie S, Tschernia Nicholas, Dotti Gianpietro, Savoldo Barbara
机构信息
Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
出版信息
J Clin Oncol. 2021 Feb 10;39(5):499-513. doi: 10.1200/JCO.20.01738. Epub 2021 Jan 12.
Abstract
摘要
相似文献
1
Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19 Tumors.拓展嵌合抗原受体T细胞疗法的前景：超越靶向CD19肿瘤
J Clin Oncol. 2021 Feb 10;39(5):499-513. doi: 10.1200/JCO.20.01738. Epub 2021 Jan 12.
2
Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.纳米颗粒在细胞治疗时代的前景与局限：以靶向 CD19 的嵌合抗原受体（CAR）修饰 T 细胞为例。
Int J Pharm. 2017 Nov 5;532(2):813-824. doi: 10.1016/j.ijpharm.2017.07.075. Epub 2017 Jul 29.
3
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.我如何预防接受针对 B 细胞恶性肿瘤的 CD19 靶向嵌合抗原受体 T 细胞治疗的患者感染。
Blood. 2020 Aug 20;136(8):925-935. doi: 10.1182/blood.2019004000.
4
Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.嵌合抗原受体 T 细胞疗法的耐药机制及在 B 细胞血液恶性肿瘤中的克服策略。
Int J Mol Sci. 2019 Oct 10;20(20):5010. doi: 10.3390/ijms20205010.
5
Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients.CD19靶向嵌合抗原受体T细胞免疫疗法接受者对三剂mRNA SARS-CoV-2疫苗的免疫反应。
Cancer Cell. 2022 Mar 14;40(3):236-237. doi: 10.1016/j.ccell.2022.01.010. Epub 2022 Jan 25.
6
CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.嵌合抗原受体 T 细胞疗法在血液系统恶性肿瘤中的应用：征途漫漫。
Clin Pharmacol Ther. 2020 Jan;107(1):112-122. doi: 10.1002/cpt.1674. Epub 2019 Nov 25.
7
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.嵌合抗原受体 T 细胞（CAR-T）疗法在癌症中的风险和益处：系统评价和荟萃分析。
Transfus Med Rev. 2019 Apr;33(2):98-110. doi: 10.1016/j.tmrv.2019.01.005. Epub 2019 Feb 14.
8
The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体 T 细胞疗法的免疫生物学中肠道微环境和个体微生物的潜在作用。
Front Immunol. 2021 May 31;12:670286. doi: 10.3389/fimmu.2021.670286. eCollection 2021.
9
Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.用于治疗B细胞恶性肿瘤的抗CD19和抗CD20嵌合抗原受体修饰的T细胞：一项系统评价和荟萃分析。
Immunotherapy. 2017 Sep;9(12):979-993. doi: 10.2217/imt-2017-0062.
10
Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.嵌合抗原受体 T 细胞免疫疗法治疗人 B 细胞来源血液系统恶性肿瘤
Cells. 2024 Apr 9;13(8):662. doi: 10.3390/cells13080662.
本文引用的文献
1
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.抗 CD30 CAR-T 细胞疗法在复发/难治性霍奇金淋巴瘤中的应用。
J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23.
2
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.用于急性髓系白血病的嵌合抗原受体T细胞：现状与未来方向
Front Oncol. 2020 May 6;10:697. doi: 10.3389/fonc.2020.00697. eCollection 2020.
3
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.系统性优化的 BCMA/CS1 双特异性 CAR-T 细胞强力控制异质性多发性骨髓瘤。
Nat Commun. 2020 May 8;11(1):2283. doi: 10.1038/s41467-020-16160-5.
4
A bispecific approach to improving CAR T cells in AML.一种改善急性髓系白血病中嵌合抗原受体T细胞的双特异性方法。
Blood. 2020 Mar 5;135(10):703-704. doi: 10.1182/blood.2020004791.
5
CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.嵌合抗原受体 T 细胞靶向 CD44v6 控制肺和卵巢腺癌荷瘤小鼠的肿瘤生长。
Front Immunol. 2020 Feb 4;11:99. doi: 10.3389/fimmu.2020.00099. eCollection 2020.
6
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia.双特异性和分裂嵌合抗原受体 T 细胞靶向 CD13 和 TIM3 根除急性髓系白血病。
Blood. 2020 Mar 5;135(10):713-723. doi: 10.1182/blood.2019002779.
7
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.利用 CAR 为基础的免疫疗法靶向 T 细胞恶性肿瘤：挑战与潜在解决方案。
J Hematol Oncol. 2019 Dec 29;12(1):141. doi: 10.1186/s13045-019-0801-y.
8
CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.嵌合抗原受体 T 细胞疗法在血液系统恶性肿瘤中的应用：征途漫漫。
Clin Pharmacol Ther. 2020 Jan;107(1):112-122. doi: 10.1002/cpt.1674. Epub 2019 Nov 25.
9
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.γ-分泌酶抑制增强了 BCMA 特异性嵌合抗原受体 T 细胞在多发性骨髓瘤中的疗效。
Blood. 2019 Nov 7;134(19):1585-1597. doi: 10.1182/blood.2019000050.
10
Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma.用于治疗多发性骨髓瘤的抗 GPRC5D/CD3 双特异性 T 细胞重定向抗体。
Mol Cancer Ther. 2019 Sep;18(9):1555-1564. doi: 10.1158/1535-7163.MCT-18-1216. Epub 2019 Jul 3.
Zotero 插件